Opinion

Video

Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
Patient having their blood pressure measured -- Image credit: interstid | stock.adobe.com
April 8th 2025

Study Finds ADHD Stimulants Have Minimal Effect on Cardiovascular System

Gillian McGovern, Associate Editor
Updates to Acute Coronary Syndrome Guidelines
April 8th 2025

Updates to Acute Coronary Syndrome Guidelines

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP Aislinn Antrim, Managing Editor
ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure
March 30th 2025

ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure

Aislinn Antrim, Managing Editor
Everything You Need to Know From the American College of Cardiology 2025 Scientific Session
April 1st 2025

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP Aislinn Antrim, Managing Editor
ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement
March 29th 2025

ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement

Aislinn Antrim, Managing Editor
ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots
March 29th 2025

ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots

Aislinn Antrim, Managing Editor